Medicsight releases ColonCADT 4.1 (7742D)

TIDMMDST

RNS Number : 7742D

Medicsight Plc

29 March 2011

 
 Press Release   29 March 2011

Medicsight PLC

("Medicsight" or "the Company")

Medicsight releases ColonCAD(TM) 4.1

New software provides faster results for radiologists without compromise in accuracy

Medicsight PLC (AIM: MDST), an industry leader in the development of Computer-Aided Detection (CAD) and medical image analysis software is pleased to announce the release of ColonCAD(TM) 4.1, the latest version of its computer-aided detection software. The software is designed to assist radiologists in the detection of colorectal polyps in CT Colonography image data.

ColonCAD 4.1 has a number of improvements over the previous version of the software, including the addition of Windows 7 to its list of supported Operating Systems. Version 4.1 now offers full 64-bit support, and is compatible with the 64-bit version of all its supported versions of Microsoft(R) Windows(R) .

In addition, improvements in Version 4.1 have significantly reduced processing time, with savings of up to 50% in the time taken to process image data.

The latest ColonCAD improvements are designed to support optimised workflow when reviewing of CT colonography image data. Clinical research(1) has already demonstrated that ColonCAD detected more than 96% of patients with a clinically significant colonic polyp of 10 mm or larger in size, and more than 90% of individual polyps of 6 mm or larger. On average, ColonCAD returned less than five false positive marks per image series. This research reviewed CAD performance when applied to the CT colonography images of more than 3000 patients from a colorectal cancer screening programme.

Allan Rowley, CEO of Medicsight, said: "ColonCAD 4.1 has been CE Marked* and will be available for sale initially in Europe through Medicsight's network of partners. While maintaining the high sensitivity and low false positive performance of Version 4.0, this latest version will cut processing times, provide benefits to workflow, and ultimately enable clinicians to review more patients."

1. Lawrence EM, Pickhardt PJ, Kim DH, Robbins JB. Colorectal Polyps: Stand-alone Performance of Computer-aided Detection in a Large Asymptomatic Screening Population. Radiology (2010) 256, 791-798

* CE marking certifies that a product has met European Directives regarding consumer safety, health or environmental requirements.

- ENDS -

For further information:

 
 Medicsight plc 
 Allan Rowley, CEO                      Tel: +44 (0)207 605 7950 
                                        www.medicsight.com 
 Daniel Stewart & Co 
 Noelle Greenaway / Oliver Rigby        Tel: +44 (0) 207 776 
                                         6550 
                                        www.danielstewart.co.uk

Media enquiries:

 
 Abchurch 
                                     www.abchurch-group.com 
 Julian Bosdet                       Tel: +44 (0) 207 398 
                                      7700 
 julian.bosdet@abchurch-group.com    Tel: +44 (0) 207 398 
   Adam Michael                       7708 
   adam.michael@abchurch-group.com 
 Simone Elviss                       Tel: +44 (0) 207 398 
                                      7728 
 simone.elviss@abchurch-group.com 
 Quincy Allan                        Tel: +44 (0) 207 398 
                                      7710 
 quincy.allan@abchurch-group.com

Notes to editors

Medicsight plc is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been developed using a large and population diverse database of verified patient CT scan data. Medicsight's ColonCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software

Medicsight's ColonCAD(TM) software uses an advanced CAD algorithm to analyse CT scans of the colon and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon.

ColonCAD can be seamlessly integrated with advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.

Forward Looking Statements

This announcement contains forward-looking statements. These statements relate to the Company's future prospects, developments and business strategies. Forward-looking statements are identified by their use of terms and phrases such as "believe", "could", "envisage", "estimate", "intend", "may" "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions.

The forward-looking statements in this announcement are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements.

This information is provided by RNS

The company news service from the London Stock Exchange

END

PRLZMGZFVRVGMZM

Medicsight (LSE:MDST)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025